alemtuzumab
Showing 1 - 25 of 135
Allogeneic Hematopoietic Cell Transplantation Trial (Alemtuzumab)
Not yet recruiting
- Allogeneic Hematopoietic Cell Transplantation
- Alemtuzumab
- (no location specified)
Aug 12, 2022
T-cell-prolymphocytic Leukemia Trial in Cologne (Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab)
Completed
- T-cell-prolymphocytic Leukemia
- Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
- Alemtuzumab
-
Cologne, GermanyUniversity Hospital Cologne
Dec 16, 2021
Leukemia Trial in Houston (Alemtuzumab, Etoposide, Dexamethasone)
Active, not recruiting
- Leukemia
- Alemtuzumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 2, 2022
Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,
Terminated
- Relapsing-Remitting Multiple Sclerosis
- Autologous Hematopoietic Stem Cell Transplantation
- +2 more
-
Hamburg, Germany
- +1 more
Mar 1, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in Münster (Alemtuzumab)
Completed
- Multiple Sclerosis, Relapsing-Remitting
- Alemtuzumab
-
Münster, GermanyUniversitätsklinikum Münster, Klinik für Allgemeine Neurologie
Oct 25, 2021
Chronic Granulomatous Disease Trial run by the NIAID (Sirolimus, Cyclophosphamide, Alemtuzumab)
Recruiting
- Chronic Granulomatous Disease
- Sirolimus
- +7 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 23, 2022
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Austria (Bendamustine, Alemtuzumab)
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- Bendamustine
- Alemtuzumab
-
Innsbruck, Tirol, Austria
- +6 more
Feb 15, 2022
Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)
Active, not recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Hackensack, New JerseyHackensack University Medical Center
Feb 4, 2022
Hemophagocytic Lymphohistiocytosis (HLH) Trial in Paris (Alemtuzumab, Methyl Prednisolone (MP), Cyclosporin A (CSA))
Completed
- Hemophagocytic Lymphohistiocytosis (HLH)
- Alemtuzumab
- +2 more
-
Paris, FranceHôpital Necker-Enfants Malades
Apr 13, 2021
Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)
Recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jul 31, 2022
Neurofilaments for NEDA Assessing in MS
Terminated
- Multiple Sclerosis
- Alemtuzumab
-
London, England, United KingdomQueen Mary University of London
Feb 9, 2022
Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +8 more
-
Eden Prairie, MinnesotaOptumInsight
Jan 9, 2023
Renal Transplantation Trial in United States (Alemtuzumab, rabbit antithymocyte globulin, Belatacept)
Completed
- Renal Transplantation
- Alemtuzumab
- +5 more
-
San Francisco, California
- +7 more
Jul 8, 2021
Sickle Cell Disease Trial in Saint Louis (drug, radiation, procedure)
Terminated
- Sickle Cell Disease
- Alemtuzumab
- +6 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 28, 2022
Acute Lymphoblastic Leukemia Trial in La Jolla, San Diego (Alemtuzumab, Clofarabine)
Terminated
- Acute Lymphoblastic Leukemia
- Alemtuzumab
- Clofarabine
-
La Jolla, California
- +2 more
Jul 29, 2020
Sickle Cell Anemia, Beta Thalassemia Trial run by the NHLBI (radiation, drug, biological)
Recruiting
- Sickle Cell Anemia
- Beta Thalassemia
- TBI
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 19, 2022
Sickle Cell Disease, Beta Thalassemia Trial in New York (Busulfan, Fludarabine, Alemtuzumab)
Active, not recruiting
- Sickle Cell Disease
- Beta Thalassemia
- Busulfan
- +3 more
-
New York, New YorkMorgan Stanley Children's Hospital, New York-Presbyterian, Colum
Aug 12, 2021
Sickle Cell Disease Trial in Chicago (Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus)
Recruiting
- Sickle Cell Disease
- Allogeneic Non-Myeloablative Stem Cell Transplantation
- +2 more
-
Chicago, IllinoisUniversity of Illinois at Chicago
Feb 16, 2022
Congenital Hemolytic Anemia, Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Peripheral
Recruiting
- Congenital Hemolytic Anemia
- Sickle Cell Disease
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 18, 2022
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation Trial run by the National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
- Sickle Cell Disease
- +3 more
- Alemtuzumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Idiopathic Pulmonary Fibrosis, Emphysema or COPD Trial in Pittsburgh (CD3/CD19 negative hematopoietic stem cells, Rituximab,
Recruiting
- Idiopathic Pulmonary Fibrosis
- Emphysema or COPD
- CD3/CD19 negative hematopoietic stem cells
- +6 more
-
Pittsburgh, Pennsylvania
- +1 more
Feb 9, 2022
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia Trial in
Completed
- B-cell Chronic Lymphocytic Leukemia
- +4 more
- alemtuzumab
- +9 more
-
Rochester, MinnesotaMayo Clinic
Jun 11, 2020
Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder Trial in Calgary (Alemtuzumab, Total Body
Recruiting
- Sickle Cell Disease
- +3 more
- Alemtuzumab
- +2 more
-
Calgary, Alberta, CanadaAlberta Children's Hospital
May 25, 2021